AzTrials
AzTrials

PTSDMOST for PTSDNCT06956781

Multiphase Optimization Strategy (MOST) for Treating Pediatric Post-traumatic Stress Disorder (PTSD)

A study testing Emotion Regulation, Exposure and Cognitive Processing in people with PTSD and Trauma, run by University of Rochester at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to test the extent to which different treatment components work to improve pediatric post-traumatic stress disorder (PTSD). It will also provide evidence for how these components work. Read more about this study

Who is it for?
Ages 8 to 17 years
Conditions the study is for
PTSD, Trauma, Pediatric ALL
What is being tested?
Emotion Regulation, Exposure and Cognitive Processing
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
200 participants
Where
1 siteUnited States
Study dates
15 Mar 2026to Aug 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • A child between the ages of 8-17 exposed to at least one DSM-defined trauma
  • Child assent for participation
  • The participation of a caregiver with custodial rights to provide parental permission
  • Willing to participate in treatment delivery and respond to surveys
  • Meet PTSD diagnostic criteria that is the result of exposure to at least one of the identified traumas
  • Ability to read and understand English
Show all 10Show fewer
  • Willingness to be randomized to an experimental condition
  • Placement in a stable caregiving environment for two months without an impending transition
  • Children currently taking psychotropic medications must have taken the medicine without dose adjustment for two months prior to study entry.
  • Caregiver or child with a smartphone capable of downloading a freely available software application.

Who cannot join

  • Psychiatric concerns requiring a higher level of care (e.g. suicidal ideation with intent; current psychotic disorder)
  • An intelligence quotient (IQ) < 70
  • Currently receiving a behavioral health intervention for concerns related to PTSD or pediatric trauma
  • A participating caregiver who is a perpetrator of any identified trauma (e.g. sexual abuse)
  • MRI contraindicators (e.g. presence of metal in the body)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site, 1 recruiting
  • The Mt. Hope Family Center

    Rochester, New York, 14608

    Haley Trehern, BS, 585-481-7609, haley_trehern@urmc.rochester.edu

    Chad Shenk, PhD, 585-273-3264, chad.shenk@rochester.edu

    Recruiting

Other trials in United States

About this study

Official title: Optimizing Behavioral Health Services Following Pediatric Trauma Exposure

The goal of this clinical trial is to test the extent to which different treatment components work to improve pediatric post-traumatic stress disorder (PTSD). It will also provide evidence for how these components work. The main research questions are:

What are the effects of different components used to treat PTSD? What do these components change to produce benefits in PTSD?

Read more

Researchers will:

Compare components to a psychological placebo to estimate their effects and measure how they work

Examine how components work alone and in conjunction with other components

Participants will:

Receive different combinations of components and placebo

Attend weekly treatment sessions

Provide information to evaluate changes in PTSD

Being tested
Emotion Regulation, Exposure, Cognitive Processing, Bi-lateral Stimulation, Psychological Placebo
Keywords
PTSD, Trauma, Pediatric, Multiphase Optimization Strategy
Medical subject headings
Stress Disorders, Post-Traumatic, Wounds and Injuries, Precursor Cell Lymphoblastic Leukemia-Lymphoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Emotion RegulationBehavioural

    Participants learn to reduce acute subjective distress, stabilize negative mood, promote positive mood, and alter physiological responses to trauma

  • ExposureBehavioural

    Participants engage in written exercises to reduce avoidance of trauma reminders and reinforce approach behaviors consistent with personal goals

  • Cognitive ProcessingBehavioural

    Participants learn ways to identify, challenge, and overcome the influence of cognitive distortions resulting from trauma exposure

  • Bi-lateral StimulationBehavioural

    Participants engage in horizontal eye movements while recalling a traumatic memory and describing their affective and physiological state

  • Psychological PlaceboBehavioural

    Participants receive non-directive support therapy, where they will guide the treatment session but not be required to discuss prior trauma exposure

Study groups in NCT06956781
Study groupRoleWhat they receive
Treatment Condition 1ExperimentalParticipants receive emotion regulation, exposure, cognitive processing, and bi-lateral stimulation
Receives: Behavioral: Emotion Regulation; Behavioral: Exposure; Behavioral: Cognitive Processing; Behavioral: Bi-lateral Stimulation
Treatment Condition 2ExperimentalParticipants receive emotion regulation, exposure, cognitive processing, and psychological placebo
Receives: Behavioral: Emotion Regulation; Behavioral: Exposure; Behavioral: Cognitive Processing; Behavioral: Psychological Placebo
Treatment Condition 3ExperimentalParticipants receive emotion regulation, exposure, bi-lateral stimulation, and psychological placebo
Receives: Behavioral: Emotion Regulation; Behavioral: Exposure; Behavioral: Bi-lateral Stimulation; Behavioral: Psychological Placebo
Treatment Condition 4ExperimentalParticipants receive emotion regulation, exposure, and psychological placebo
Receives: Behavioral: Emotion Regulation; Behavioral: Exposure; Behavioral: Psychological Placebo
Treatment Condition 5ExperimentalParticipants receive emotion regulation, cognitive processing, bi-lateral stimulation, and psychological placebo
Receives: Behavioral: Emotion Regulation; Behavioral: Cognitive Processing; Behavioral: Bi-lateral Stimulation; Behavioral: Psychological Placebo
Treatment Condition 6ExperimentalParticipants receive emotion regulation, cognitive processing, and psychological placebo
Receives: Behavioral: Emotion Regulation; Behavioral: Cognitive Processing; Behavioral: Psychological Placebo
Treatment Condition 7ExperimentalParticipants receive emotion regulation, bi-lateral stimulation, and psychological placebo
Receives: Behavioral: Emotion Regulation; Behavioral: Bi-lateral Stimulation; Behavioral: Psychological Placebo
Treatment Condition 8ExperimentalParticipants receive emotion regulation and psychological placebo
Receives: Behavioral: Emotion Regulation; Behavioral: Psychological Placebo
Treatment Condition 9ExperimentalParticipants receive exposure, cognitive processing, bi-lateral stimulation, and psychological placebo
Receives: Behavioral: Exposure; Behavioral: Cognitive Processing; Behavioral: Bi-lateral Stimulation; Behavioral: Psychological Placebo
Treatment Condition 10ExperimentalParticipants receive exposure, cognitive processing, and psychological placebo
Receives: Behavioral: Exposure; Behavioral: Cognitive Processing; Behavioral: Psychological Placebo
Treatment Condition 11ExperimentalParticipants receive exposure, bi-lateral stimulation, and psychological placebo
Receives: Behavioral: Exposure; Behavioral: Bi-lateral Stimulation; Behavioral: Psychological Placebo
Treatment Condition 12ExperimentalParticipants receive exposure and psychological placebo
Receives: Behavioral: Exposure; Behavioral: Psychological Placebo
Treatment Condition 13ExperimentalParticipants receive cognitive processing, bi-lateral stimulation, and psychological placebo
Receives: Behavioral: Cognitive Processing; Behavioral: Bi-lateral Stimulation; Behavioral: Psychological Placebo
Treatment Condition 14ExperimentalParticipants receive cognitive processing and psychological placebo
Receives: Behavioral: Cognitive Processing; Behavioral: Psychological Placebo
Treatment Condition 15ExperimentalParticipants receive bi-lateral stimulation and psychological placebo
Receives: Behavioral: Bi-lateral Stimulation; Behavioral: Psychological Placebo
Treatment Condition 16ExperimentalParticipants receive psychological placebo
Receives: Behavioral: Psychological Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean Change in PTSD Symptoms - Clinician Administered PTSD Scale for DSM-5 - Child/Adolescent Version (CAPS-CA)

    The CAPS-CA is a clinician-administered diagnostic interview measuring the severity of PTSD symptoms in the past month. The interview assesses 20 PTSD symptoms according to DSM-5 diagnostic criteria with each symptom rated on a severity scale ranging from 0 to 4. Ratings for each individual symptom are summed with higher scores indicating greater severities of PTSD symptoms (total scores range from 0-80).

    Measured: Baseline (pre-treatment), Week 19 (post-treatment)

  2. Mean Change in PTSD Symptoms - Child PTSD Symptom Scale for DSM-5 (CPSS)

    The CPSS is a child-report survey measuring the severity of PTSD symptoms in the past month. Survey items assess 20 PTSD symptoms according to DSM-5 diagnostic criteria with severity ratings for each item ranging from 0-4. Ratings for each individual symptom are summed with higher scores indicating greater severities of PTSD symptoms (total scores range from 0-80).

    Measured: Baseline (pre-treatment), Week 19 (post-treatment)

  3. Mean Change in PTSD Symptoms - Child and Adolescent Trauma Screen (CATS-2)

    The CATS-2 is a caregiver-reported survey measuring the frequency of pediatric PTSD symptoms in the past four weeks. Survey items assess 20 PTSD symptoms according to DSM-5 and ICD-11 diagnostic criteria with frequency ratings for each item ranging from 0-3. Ratings for each individual item are summed with higher scores indicating greater frequencies of PTSD symptoms (total scores range from 0-60).

    Measured: Baseline (pre-treatment), Week 19 (post-treatment)

Secondary outcomes (19)
  1. Change in the Number of Participants with a PTSD Diagnosis - The Clinician Administered PTSD Scale for DSM-5 - Child / Adolescent Version (CAPS-CA)

    The CAPS-CA is a clinician-administered interview establishing the presence of a PTSD diagnosis according to DSM-5 diagnostic criteria. The presence of a PTSD diagnosis (yes/no) will be established before and after receiving treatment. Change in PTSD diagnostic status will be used to indicate treatment response.

    Measured: Baseline (pre-treatment), Week 19 (post-treatment)

  2. Change in PTSD Symptom Trajectories - Child PTSD Symptom Scale for DSM-5 (CPSS)

    The CPSS is a child-report survey measuring the severity of PTSD symptoms that will be modified to assess these symptoms in the time since the last treatment session. Survey items assess 20 PTSD symptoms according to DSM-5 diagnostic criteria with severity ratings for each item ranging from 0-4. Ratings for each individual symptom are summed with higher scores indicating greater severities of PTSD symptoms (total scores range from 0-80).

    Measured: Baseline (pre-treatment), Weeks 1-18 (active treatment), Week 19 (post-treatment)

  3. Change in PTSD Symptom Trajectories - Child and Adolescent Trauma Screen (CATS-2)

    The CATS-2 is a caregiver-reported survey measuring the frequency of pediatric PTSD symptoms that will be modified to assess these symptoms in the time since the last treatment session. Survey items assess 20 PTSD symptoms according to DSM-5 and ICD-11 diagnostic criteria with frequency ratings for each item ranging from 0-3. Ratings for each individual item are summed with higher scores indicating greater frequencies of PTSD symptoms (total scores range from 0-60).

    Measured: Baseline (pre-treatment), Weeks 1-18 (active treatment), Week 19 (post-treatment)

  4. Mean Change in Mood Disorder Symptoms - Children's Depression Inventory-2 (CDI-2)

    The CDI-2 is a child-report survey assessing the severity of twenty-eight mood disorder symptoms in the past two weeks. Responses are rated on a scale from 0-2 and summed. Higher scores indicate greater severities of mood disorder symptoms (total raw scores range from 0-56). Raw scores can be converted to T-scores.

    Measured: Baseline (pre-treatment), Week 19 (post-treatment)

  5. Mean Change in Anxiety Disorder Symptoms - Screen for Child Anxiety Related Disorders (SCARED)

    The SCARED is a child-report survey assessing symptoms of five pediatric anxiety disorders (panic/somatic, generalized anxiety, separation anxiety, social phobia, and school phobia) in the past three months. Responses assess the presence of 41 anxiety symptoms on a scale ranging from 0-2. Item responses are summed with higher scores indicating more severe anxiety symptoms (total scores range from 0-82).

    Measured: Baseline (pre-treatment, Week 19 (post-treatment)

  6. Mean Change in Disruptive Behavior Disorder Symptoms - Child Behavior Checklist (CBCL)

    The CBCL is a caregiver-report survey measuring the frequency of child behavior problems in the past six months, including disruptive behavior disorder symptoms. There are 112 items rated on a scale of 0-2 with individual item ratings summed to indicate greater symptom frequency (total scores range from 0-238). Raw scores can be converted to T-scores. The externalizing disorders broadband scale and the DSM-oriented scales will be used to measure disruptive behavior disorder symptoms.

    Measured: Baseline (pre-treatment), Week 19 (post-treatment)

  7. Change in PTSD, Mood, Anxiety, and Disruptive Behavior Disorder Symptom Trajectories - Ecological Momentary Assessment (EMA)

    A 29-item, once-daily EMA will be administered to children via smartphone application for a period of two-weeks at pre-treatment, mid-treatment, and post-treatment. Items assess the presence and duration of PTSD, mood, anxiety, and disruptive behavior disorder symptoms on a scale from 0-100. Higher scores indicate a longer duration of symptoms experienced for the day the survey is completed.

    Measured: Baseline (pre-treatment), A randomly selected two-week period during active treatment (Weeks 5-18), Week 19 (post-treatment)

  8. Changes in Trajectories of C-Reactive Protein (CRP)

    The Tasso+ device will be used to obtain whole blood samples. Tasso+ is an FDA 510(k)-approved, sterile, disposable blood lancing device approved for use by laypeople (e.g. caregiver, research staff). A sterile lancet punctures the skin with the press of a button that simultaneously creates a slight vacuum to help capillary blood flow into a compatible tube under gravity. Depending on blood yield, CRP will be assayed.

    Measured: Baseline (pre-treatment), A randomly selected two-week period during active treatment (Weeks 5-18), Week 19 (post-treatment)

  9. Changes in Trajectories of Interleukin-6 (IL-6)

    The Tasso+ device will be used to obtain whole blood samples. Tasso+ is an FDA 510(k)-approved, sterile, disposable blood lancing device approved for use by laypeople (e.g. caregiver, research staff). A sterile lancet punctures the skin with the press of a button that simultaneously creates a slight vacuum to help capillary blood flow into a compatible tube under gravity. Depending on blood yield, IL-6 will be assayed.

    Measured: Baseline (pre-treatment), A randomly selected two-week period during active treatment (Weeks 5-18), Week 19 (post-treatment)

  10. Changes in Trajectories of Tumor Necrosis Factor-Alpha

    The Tasso+ device will be used to obtain whole blood samples. Tasso+ is an FDA 510(k)-approved, sterile, disposable blood lancing device approved for use by laypeople (e.g. caregiver, research staff). A sterile lancet punctures the skin with the press of a button that simultaneously creates a slight vacuum to help capillary blood flow into a compatible tube under gravity. Depending on blood yield, tumor necrosis factor-alpha will be assayed.

    Measured: Baseline (pre-treatment), A randomly selected two-week period during active treatment (Weeks 5-18), Week 19 (post-treatment)

  11. Brain Aging - Magnetic Resonance Imaging (MRI)

    MRIs will be performed to measure changes in brain aging, the difference between a participant's chronological age and biological age estimated through several established neural markers. Positive brain aging scores indicate faster brain aging. Negative brain aging scores indicate slower brain aging.

    Measured: Baseline (pre-treatment), A randomly selected two-week period during active treatment (Weeks 5-18), Week 19 (post-treatment)

  12. Change in Neural Structure - Magnetic Resonance Imaging (MRI)

    MRIs will be performed to measure changes in neural structures (e.g. hippocampal and amygdala volume) involved in memory retrieval as well as threat and fear processing associated with PTSD and treatment of PTSD.

    Measured: Baseline (pre-treatment), A randomly selected two-week period during active treatment (Weeks 5-18), Week 19 (post-treatment)

  13. Change in Network Connectivity - Magnetic Resonance Imaging (MRI)

    MRIs will be performed to measure changes in network connectivity (e.g. default mode network) related to working memory performance, autobiographical recall, and fear processing.

    Measured: Baseline (pre-treatment), A randomly selected two-week period during active treatment (Weeks 5-18), Week 19 (post-treatment)

  14. Mean Change in Experiential Avoidance - Avoidance and Fusion Questionnaire for Youth (AFQ-Y)

    The AFQ-Y is a 17-item child report survey assessing experiential avoidance in the presence of aversive private stimuli. Items are anchored on a 0-4 scale with responses summed to indicate greater levels of avoidance (total scores range from 0-68).

    Measured: Baseline (pre-treatment), Week 19 (post-treatment)

  15. Mean Change in Trauma-Related Cognitions - Child Post-Traumatic Cognitions Inventory (CPTCI)

    The CPTCI is a 25-item measure assessing the presence of different cognitions that may occur following exposure to pediatric trauma. Each item is ranked on a 1-4 scale with individual responses summed to indicate a greater number of trauma-related cognitions (total scores range from 25-100).

    Measured: Baseline (pre-treatment), Week 19 (post-treatment)

  16. Mean Change in Emotion Transitions - Affect Transition Task

    Subjects rate the likelihood that a person would transition between two hypothetical affective states. In each trial, subjects are presented with two states connected by an arrow (e.g. happy - angry) and are informed that the state to the left of the arrow is the person's current state and the state on the right side of the arrow is a state the person might experience next. The states included are: hate, love, happy, hurt, mad, sad, scared, and tired. Subjects then rate the likelihood of that person making that transition on a continuous scale from 0-100% with higher scores indicating a greater likelihood of that transition. For a second set of tasks, subjects rate the similarity between each pair of states using a scale from 0-100% with higher ratings indicating greater similarity. Variation in the likelihood ratings for each paired states are examined across participants.

    Measured: Baseline (pre-treatment), Week 19 (post-treatment)

  17. Mean Change Subclinical Psychosis - Prodromal Questionnaire Brief Child Version Screener (PQ-BC)

    The PQ-BC is a 21-item child-report survey assessing subclinical psychotic symptoms, including unusual beliefs and perceptual distortions in the past month. Each item assesses the presence of a subclinical psychotic symptom in a yes/no response format. A distress score, which weights the endorsed item by the level of distress experienced by that item on a scale of 0-6, is obtained for each of the 21 items. Total scores range from 0-126 with higher scores indicating greater distress.

    Measured: Baseline (pre-treatment), Week 19 (post-treatment)

  18. Mean Change Transdiagnostic Psychiatric Symptoms - The Kiddie Schedule for Affective Disorders and Schizophrenia - Cross Cutting Symptoms (K-SADS-CC)

    The K-SADS-CC is a 21-item child-report survey assessing psychiatric symptoms common across different psychiatric disorders. Each item assesses the severity of a psychiatric symptom during the past two weeks on a scale of 0-4. Total scores range from 0-84 with higher scores indicating a greater severity of psychiatric symptoms.

    Measured: Baseline (pre-treatment), Week 19 (post-treatment)

  19. Mean Change Transdiagnostic Psychiatric Symptoms - The Kiddie Schedule for Affective Disorders and Schizophrenia - Cross Cutting Symptoms (K-SADS-CC)

    The NIDA mASSIST is a 15-item child-report survey assessing the use of substances. Each item assesses the frequency of use for a specified substance during the past two weeks on a scale of 0-4. Change in the use of individual substances can be examined over time. A polysubstance use severity score can also be generated by summing the frequencies of all individual items. Total scores for the polysubstance use severity score range from 0-84 with higher scores indicating a greater severity of substance use.

    Measured: Baseline (pre-treatment), Week 19 (post-treatment)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 May 2025
  2. Study start15 Mar 2026
  3. Primary completionAug 2028 (estimated)
  4. Study completionAug 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Model description
2\^4 Full Factorial Randomized Clinical Trial
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06956781
Sponsor's protocol ID
STUDY00010448
Acronym
MOST for PTSD
Status last verified
Apr 2026
First submitted
24 Apr 2025
Last updated
8 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified data and analytic code will be shared on open science outlets

Questions about this trial

What is this clinical trial studying?

A study testing Emotion Regulation, Exposure and Cognitive Processing in people with PTSD and Trauma, run by University of Rochester at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Chad E Shenk, PhD ((585) 275-8704, chad.shenk@rochester.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean Change in PTSD Symptoms - Clinician Administered PTSD Scale for DSM-5 - Child/Adolescent Version (CAPS-CA) (time frame: Baseline (pre-treatment), Week 19 (post-treatment)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in